Intrexon sees future in genetically modified (GM) animal produce, buys 48% stake in genetically modified fish research firm Aquabounty from firm of Georgian ex-scientist turned oligarch with plans to become supermajority stakeholder.

Specialty pharmaceutical company Aclaris Therapeutics raises $21m in a Series A round led by Vivo Ventures.

Nokia joins forces with the Kenyan government to develop health and education innovations.

Canada-based Alethia BioTheraputics has received $4.7m in venture capital funding which it will use to fund its antibody therapeutics program for cancer.

Reflexion is West Health's second incubated start-up.

In July last year, SR One and Lilly Ventures, the corporate venturing divisions of multinational pharmaceutical conglomerates GlaxoSmithKline and Eli Lilly respectively, co-led a $24m series A round for Nimbus Discovery.

In May 2010, Resolve raised $2m in the initial close of its A round before bringing in a corporate venturing unit later.

Medtronic is paying $46.6m at HK3.80 per share for a 19% equity interest in the Chinese company, followed by a $19.6m convertible note for an additional 7.4% stake.

In May 2010, Resolve raised $2m in the initial close of its A round before bringing in a corporate venturing unit later.